Trump’s 'Donroe Doctrine' Aims to Dominate the Americas (The Wall Street Journal): The White House is turning a 19th-century ...

Very local, powered by KSPWA local news, learning new information. Original series and specials, it's pretty awe inspiring. 24/7 TV made just for you. How awesome is this? Download the free very local ...

Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo. The Food and Drug Administration (FDA) has approved Libtayo ® (cemiplimab-rwlc) for the ...

BRADENTON, Fla. (WFLA) — Bradenton police officers are searching for a person who was seen committing a smash-and-grab burglary at a laundromat. The Bradenton Police Department said the person ...

TL;DR: EA's $55 billion leveraged buyout, the largest in history, will saddle the company with $20 billion in debt funded by a potentially high-risk loan, which could prompt cost-cutting, layoffs, and ...

As many as one third of newly diagnosed multiple myeloma (MM) cases are classified as high risk, with widely varying rates of progression-free survival (PFS), as shown in a validation of consensus ...

Sept. 29 (UPI) --The Trump administration on Monday rescinded a Biden-era firearms export rule that prohibited the transfer of civilian weaponry to individuals in 36 countries deemed high-risk of ...

In this article, we will be looking at 12 high-risk high-reward growth stocks to buy right now. The Federal Reserve has cut its benchmark lending rate to 4.00%-4.25% ...

MRD-guided retreatment with anti-CD20 antibodies may improve survival outcomes in high-risk, relapsed CLL patients by initiating therapy before clinical relapse. The study showed MRD-triggered ...

Molecular profiling has transformed cancer care, but 30% of high-risk pediatric cancers do not have actionable therapeutic targets, limiting personalized treatment options and negatively affecting ...

TORONTO -- Linvoseltamab (Lynozyfic) appeared effective in patients with high-risk smoldering multiple myeloma (HR-SMM), according to preliminary phase II trial data. With a median follow-up of 3.9 ...